I

ImmunityBio, Inc.

IBRX Nasdaq Healthcare · Biological Products, (No Diagnostic Substances) San Diego, CA immunitybio.com
$8.49
Mkt Cap 8.59B
Forward-Looking Statements This Annual Report contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act that are based on our mana…

Forward-Looking Statements This Annual Report contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act that are based on our management’s beliefs and assumptions and on information currently available to our management. Forward-looking statements include, but are not limited to: our ability to successfully commercialize ANKTIVA globally in NMIBC, NSCLC or other indications or any future approved products in the U.S.

Source: annual report (Form 10-K) filed 2026-02-23 — SEC EDGAR
—
/100 Overall
Calculating score…
Running full analysis
Ready to value this company?
Run a full DCF model with Monte Carlo simulation.
Run DCF Valuation →
📊 Key Metrics
Loading full analysis…
REVENUE TTM
$165.8M
184.8% CAGR
FCF TTM
-$288.1M
-173.8% margin
Running full 6-factor analysis…